Johnson & Johnson just agreed to pay $5.5 billion to settle roughly 99,000 lawsuits alleging its talc-based baby powder caused ovarian cancer, closing out what has been one of the most protracted product liability fights in American corporate history. The settlement covers nearly all remaining claims, and plaintiffs' attorneys confirmed Monday that it was a good resolution after more than a decade of legal combat.

The number is large. But the timing matters just as much as the dollar figure.

How J&J got here

J&J has consistently denied that its talc products caused cancer or contained asbestos. The company stopped selling talc-based baby powder in the United States in 2020, switching to a cornstarch formula. But tens of thousands of women, most diagnosed with ovarian cancer, kept pressing their claims.

For more than three years, those claims sat frozen while J&J attempted an unusual legal maneuver: funneling the lawsuits into a bankruptcy proceeding run by a shell company it created specifically to handle the litigation. The strategy, known as a "Texas two-step," was designed to cap J&J's liability at a number the company preferred. Courts repeatedly rejected it, and the litigation restarted in March 2025 with the cases back in federal and state courts.

Then, last week, a federal judge cast serious doubt on whether individual plaintiffs could prove that talc specifically, rather than some other factor, caused their ovarian cancer. That ruling gave J&J real legal leverage. Within days, the company had a deal.

What $5.5 billion means in practice

The settlement resolves about 69,000 cases consolidated in federal court, plus related state cases, representing 99.75 percent of the remaining claims.

For the women who sued, or for families of women who died before the case resolved, this is the end of the road after years of waiting. How much any individual plaintiff receives depends on the allocation process that comes next, which plaintiffs' attorneys will oversee. In mass tort settlements of this kind, individual payouts vary enormously based on severity of illness, age at diagnosis, and other factors. The total sounds enormous; spread across nearly 100,000 cases, the average works out to roughly $55,000 per claimant before legal fees, though individual outcomes will range widely above and below that figure.

For J&J, a company with annual revenue exceeding $88 billion, $5.5 billion is painful but survivable. It is also, from J&J's perspective, a known and finite cost. The alternative, continuing to litigate thousands of individual trials, carries the risk of runaway jury verdicts that are impossible to predict or budget.

The bigger pattern

This case is a window into how corporate America handles mass product liability in the 21st century. The bankruptcy maneuver J&J attempted and the courts rejected was designed precisely to prevent the kind of open-ended individual-trial exposure that plaintiffs' lawyers use as leverage. When that strategy failed, J&J fell back on something more traditional: a lump-sum settlement timed to follow a favorable court ruling that weakened the other side's position.

The result is neither a full victory nor a full loss for either side. Plaintiffs get money but not a public finding that J&J's product was responsible for their illness. J&J pays billions but admits nothing and avoids the reputational exposure of trial testimony. That outcome, accountability traded for certainty, is how most large-scale litigation ends in the United States, regardless of what the underlying facts might eventually show.

The talc product itself is already off the U.S. market. What this settlement closes is the legal account, not the scientific question of what the product did or didn't do.